Author:
Colombini Marjorie Paris,Derogis Priscilla Bento Matos Cruz,de Aranda Valdir Fernandes,de Campos Guerra João Carlos,Hamerschlak Nelson,Mangueira Cristóvão Luis Pitangueiras
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Tripodi A. The laboratory and the direct oral anticoagulants. Blood. 2013;121(2):4032–5.
2. Leung LLK. Direct oral anticoagulants: Dosing and adverse effects. UpToDate. 2016. Available from: http://www.uptodate.com/contents/direct-oral-anticoagulants-dosing-and-adverse-effects?source=search_result&search=Direct+oral+anticoagulants&selectedTitle=1%7E131 . Accessed in 2017 (May 15).
3. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban – an oral, direct factor FXa inhibitor. Blood. 2006;108:905. Available from: http://www.bloodjournal.org/content/108/11/905?sso-checked=true . Accessed in 2017 (May 15).
4. Tripodi A. The laboratory and the new oral anticoagulants. Clin Chem. 2013;59(2):353–62.
5. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation Committee of the International Society on thrombosis and haemostasis. J Thromb Haemost. 2013;11:756–760.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献